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Available online 3 May 2019Background: Several treatment approaches in cystic fibrosis (CF) aim to correct CF transmembrane con-
ductance regulator (CFTR) function; the efficacy of each approach is dependent on the mutation(s)
present. A need remains for more effective treatments to correct functional deficits caused by the
F508del mutation.
Methods: Two placebo-controlled, phase 2a studies evaluated GLPG2222, given orally once daily
for 29 days, in subjects homozygous for F508del (FLAMINGO) or heterozygous for F508del and a
gating mutation, receiving ivacaftor (ALBATROSS). The primary objective of both studies was to as-
sess safety and tolerability. Secondary objectives included assessment of pharmacokinetics, and of
the effect of GLPG2222 on sweat chloride concentrations, pulmonary function and respiratory symp-
toms.
Results: Fifty-nine and 37 subjects were enrolled into FLAMINGO and ALBATROSS, respectively.
Treatment-related treatment-emergent adverse events (TEAEs) were reported by 29.2% (14/48) of
subjects in FLAMINGO and 40.0% (12/30) in ALBATROSS; most were mild to moderate in severity
and comprised primarily respiratory, gastrointestinal, and infection events. There were no deaths
or discontinuations due to TEAEs. Dose-dependent decreases in sweat chloride concentrations
were seen in GLPG2222-treated subjects (maximum decrease in FLAMINGO: –17.6 mmol/L
[GLPG2222 200 mg], p b 0.0001; ALBATROSS: –7.4 mmol/L [GLPG2222 300 mg], p b 0.05). No signif-
icant effects on pulmonary function or respiratory symptoms were reported. Plasma GLPG2222Keywords:
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d ALBATROSS trials have been presented as a poster and oral presentation, respectively, at the 41st European Cystic Fibrosis
t the 32nd North American Cystic Fibrosis Conference, 18–20 October 2018 in Denver, Colorado, USA [3,4].
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701S.C. Bell et al. / Journal of Cystic Fibrosis 18 (2019) 700–707concentrations in CF subjects were consistent with previous studies in healthy volunteers and CF
subjects.
Conclusions: GLPG2222 was well tolerated. Sweat chloride reductions support on-target enhancement of
CFTR activity in subjects with F508del mutation(s). Significant improvements in clinical endpoints were
not demonstrated. Observed safety results support further evaluation of GLPG2222, including in combi-
nation with other CFTR modulators.
Funding: Galapagos NV.
Clinical trial registration numbers
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© 2019 The Authors. Published by Elsevier B.V. on behalf of European Cystic Fibrosis Society. This is an open access
article under the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).1. Introduction
Approximately 90% of people with cystic fibrosis (CF) have at
least one copy of the F508del mutation and around half of these
individuals are F508del homozygous [5]. Current treatment ap-
proaches aimed at CF transmembrane conductance regulator
(CFTR) modulation in F508del homozygous subjects have their
limitations. Lumacaftor, a CFTR corrector, demonstrated no clinical
benefit on pulmonary function and sweat chloride levels (a mea-
sure of CFTR activity) as a monotherapy in this population [6,7],
while the combination of lumacaftor and the CFTR potentiator
ivacaftor reduced pulmonary exacerbations but offered modest ef-
fects on lung function and quality of life [7–9]. Drug intolerances
necessitated frequent discontinuation particularly in individuals
with a forced expiratory volume in one second (FEV1) below or
equal to 40% treated with this combination [10,11]. In addition,
lumacaftor is a strong cytochrome P4503A inducer and drug–
drug interactions can complicate its use [12,13]. Tezacaftor is a
CFTR corrector with similar clinical efficacy to lumacaftor but is
associated with fewer adverse effects and drug–drug interactions.
In combination with ivacaftor, tezacaftor has demonstrated CFTR
channel activity with an acceptable safety profile in F508del ho-
mozygous subjects [12,14]. However, a need remains for more ef-
fective treatments for CF subjects with F508del mutation, and
novel doublet and triplet potentiator and corrector combinations
are under clinical evaluation (NCT03525444, NCT03525574,
NCT03447249, NCT03447262, NCT03500263). Class III gating mu-
tations (e.g., G551D), which result in the failure of CFTR channels
to function on the cell surface [5,15], are less common than the
F508del mutation [16] and functioning can be partially restored
with CFTR potentiators. However, as the majority of people with
a gating mutation also have the F508del mutation on their second
allele (83% in the USA [17] and 87% in Europe [18]), these patients
may benefit from being treated with a corrector in addition to a
potentiator.
GLPG2222 is a novel, potent CFTR corrector in development
for the treatment of CF [15,19,20]. In primary bronchial epithe-
lial cells from F508del homozygous subjects, GLPG2222 in com-
bination with a potentiator partially restored CFTR function and
was over 25-fold more potent than lumacaftor [15]. In phase 1
studies, GLPG2222 was well tolerated in healthy and CF sub-
jects, and single-dose pharmacokinetics (PK) were similar in
both populations [19,20]. The results from two phase 2a studies
evaluating GLPG2222 are reported here; the FLAMINGO study
(NCT03119649) in F508del homozygous subjects and the
ALBATROSS study (NCT03045523) in subjects heterozygous for
F508del and a class III gating mutation, who were receiving
ivacaftor. The primary objective of both studies was to assess
the safety and tolerability of GLPG2222. Secondary objectives
included assessment of markers of CFTR activity, pulmonary
function, respiratory symptoms, and PK.2. Methods
2.1. Study participants
Adult subjects aged ≥18 years with a confirmed clinical diagnosis of
CF were eligible for inclusion in these studies. Subjects enrolled in the
FLAMINGO study were homozygous for the F508del CFTR mutation. In
the ALBATROSS study, the main inclusion criteria were an F508del mu-
tation on one allele of the CFTR gene and a gating mutation (one of the
following: G551D, G1244E, G1349D, G178R, G551S, S1251N, S1255P,
S549N, or S549R) on the other, and a stable concomitant medication
regimen (including ivacaftor [150 mg b.d.]) for ≥4 weeks prior to first
study drug administration. In both studies, subjects were required to
have FEV1 ≥ 40% of predicted at their first baseline visit.
For both studies, exclusion criteria included: a history of clinically im-
portant concomitant disease which, in the opinion of the investigator,
made the subject unsuitable for the study; unstable pulmonary status
or respiratory tract infection (including rhinosinusitis) that necessitated
a change in therapy within 4 weeks prior to first study drug administra-
tion; and use of supplemental oxygen during the day or at a rate of
N2 L/min while sleeping. An additional exclusion criterion for the
FLAMINGO studywas the use of CFTRmodulator therapy (e.g. lumacaftor
and ivacaftor) within 4 weeks prior to first study drug administration.
The studies conformed to Good Clinical Practice guidelines and Dec-
laration of Helsinki principles, and all subjects provided written, in-
formed consent. The protocol and consent forms were approved by an
independent ethics committee/institutional review board at each
center.2.2. Study designs and procedures
Two phase 2a, multicenter, randomized, double-blind, placebo-
controlled, parallel-group trials were performed (Fig. S1). Treatments
were administered orally once daily for 29 days. GLPG2222 was admin-
istered as a tablet in the FLAMINGO study and as an oral suspension in
the ALBATROSS study (as the tablet formulation was not available at
the time of study conduct).
In the FLAMINGO study, eligible subjects were enrolled sequentially.
The first 25 subjects were randomized 2:2:1 to receive either GLPG2222
50mg, GLPG2222 100mg, or matching placebo, and the last 34 subjects
were randomized 2:2:1 to receive either GLPG2222 200 mg, GLPG2222
400mg, or matching placebo. In the ALBATROSS study, eligible subjects
were randomized 2:2:1 to receive either GLPG2222 150 mg, GLPG2222
300mg, or matching placebo in addition to their current ivacaftor treat-
ment (150mg b.d.). In both studies, randomizationwas performed via a
computerized interactive web response system. Subjects, investigators,
study coordinators, sponsor, and study team remained blinded to treat-
ment assignment until study completion. Doses of GLPG2222 were se-
lected based upon in vitro data and the exposures seen in phase 1
studies in healthy volunteers and CF subjects [15,19,20].
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The primary endpoint in both studies was safety and tolerability as
assessed by treatment-emergent adverse events (TEAEs), clinical labo-
ratory evaluations, 12-lead electrocardiogram (ECG), vital signs,
spirometry, oxygen saturation (pulse oximetry), and physical
examinations.
Secondary endpoints included the change from baseline in
sweat chloride concentration, pulmonary function, respiratory
symptoms, and PK parameters. Assessments were performed at
screening; pre-dose on days 1, 15, and 29; at early discontinua-
tion (if applicable); and at follow-up. Additional blood samples
for optional PK analysis were taken post-dose on day 15 or 29.
Spirometry (assessed for safety purposes) was also performed
1–2 h after drug administration on days 1 and 29. Sweat was
collected from both arms and chloride concentration determined
from the arm with the greatest volume (main analysis) and the
mean of both arms (sensitivity analysis). As sweat chloride de-
rived from the mean of both arms appeared to be less subject
to variability, only these data are presented. Pulmonary function
was assessed by pre-bronchodilator spirometry and data for per-
cent predicted FEV1 (ppFEV1) and change from baseline FEV1
derived from absolute FEV1 values. Respiratory symptoms were
assessed using the change from baseline in the respiratory
symptom scale score of the Cystic Fibrosis Questionnaire-
Revised (CFQ-R). Drug plasma concentrations were measured
using a validated liquid chromatography tandem mass spectrom-
etry method.
2.4. Statistical analyses
As the primary endpoint of both studies was related to safety, no
strict sample size calculations were done. However, with 50 and 35
subjects for the FLAMINGO and ALBATROSS studies, respectively, it
was possible to detect a difference between study drug doses for
sweat chloride of 14 mmol/L, at a 5% 2-sided type 1 error (assuming
a standard deviation of 10 mmol/L and with a power of 80%). No ad-
justment for multiple testing (GLPG2222 doses versus placebo) has
been carried out on this sample size calculation due to the exploratory
nature of these phase 2 studies.
The safety population consisted of all subjects who received
at least one dose of study drug. The PK population consisted ofEnroll
to one
•  GLP
•  GLP
•  Plac
B
Comp
•  GLP
•  GLP
•  Plac
Enrolled (n=59), assigned sequentially to:
•  Cohort A (n=25)
•  Cohort B (n=34)
Each cohort randomized 2:2:1 to one of the
following treatments:
•  Cohort A: GLPG2222 50 mg (n=10),
   GLPG2222 100 mg (n=10), placebo (n=5) 
•  Cohort B: GLPG2222 200 mg (n=14),
   GLPG2222 400 mg (n=14), placebo (n=6) 
Assessed for eligibility (n=73)
Analyzed (n=59)
A
Excluded (n=14; failure
to meet all inclusion
and exclusion criteria)
Fig. 1. Subject disposition for (A) the FLAMINGOstudy and (B) theALBATROSS study. *One subje
containing the GLPG2222 150mg q.d. doses and discontinued treatment upon sponsor's decisio
(once daily).subjects who were exposed to GLPG2222 and who had available
and evaluable PK data. The intent-to-treat (ITT) population
consisted of all subjects who received at least one dose of
study drug and had at least one post-baseline assessment of ef-
ficacy data. In the ALBATROSS study, one subject assigned to the
placebo group inadvertently received the 150 mg dose kit; effi-
cacy data from ALBATROSS are therefore reported for a modified
ITT (mITT) population, from which this subject was excluded.
Analysis of covariance (ANCOVA) of changes from baseline at
each time point, with treatment as factor and baseline value as
covariate, was applied to sweat chloride, FEV1, and CFQ-R data.
A sensitivity analysis was performed using non-parametric tests
(Kruskal-Wallis test for overall treatment effect and Wilcoxon
rank sum tests for pairwise comparisons versus the placebo
group) and a mixed effects model for repeated measures —
with treatment and analysis visit as fixed effects, baseline as a
covariate, treatment analysis visit as an interaction term, and
subject as random effect. Between-group comparisons were per-
formed for each dose versus placebo (pooled placebo in the
FLAMINGO study) without multiplicity correction. For efficacy
measures, missing data were primarily imputed using the last
observation carried forward method. An observed cases analysis
was also performed.3. Results
3.1. Subject disposition and baseline characteristics
The FLAMINGO study was conducted between 18 March and 19 Oc-
tober 2017 in the USA and Europe. The ALBATROSS study was con-
ducted between 23 January and 24 August 2017 in Australia and
Europe. Each study was conducted at 21 sites (Table S1).
Fifty-nine and 37 subjects were enrolled into the FLAMINGO and
ALBATROSS studies, respectively, and all received at least one dose of
study drug and were evaluated for safety. Efficacy was evaluated in 59
subjects in the ITT population in FLAMINGO and 36 subjects in the
mITT population in ALBATROSS (Fig. 1). In both studies, baseline demo-
graphics and disease characteristics were generally balanced across
groups, although ppFEV1 was higher in the placebo groups (Tables 1
& S2). In addition, baseline sweat chloride levels were lower in
ALBATROSS due to the effects of ivacaftor on the gating defect in theed (n=37), randomized 2:2:1
 of the following treatments:
G2222 150 mg (n=16)
G2222 300 mg (n=14)
ebo (n=7)
Assessed for eligibility (n=47)
Excluded (n=10;
screening failures)
leted:
G2222 150 mg (n=15)
G2222 300 mg (n=13)
ebo (n=7)
•  Discontinued after day 15 (n=1; mistakenly
   received drug instead of placebo)*
•  Withdrawal from study after day 15
   (n=1; missed day 29 and follow-up visits)
ct,whowas randomized to theplacebo treatment group, received thewrong study drug kit
n. The subject was not included in themodified intent-to-treat population. q.d., quaque die
Table 1
Baseline demographics and disease characteristics for the FLAMINGO and ALBATROSS studies (safety populations).
Parameter FLAMINGO (N = 59) ALBATROSS (+ ivacaftor; N = 37)
Pooled
placebo
(n = 11)
GLPG2222 50 mg
q.d. (n = 10)
GLPG2222 100 mg
q.d. (n = 10)
GLPG2222 200 mg
q.d. (n = 14)
GLPG2222
400 mg
q.d. (n = 14)
Placebo
(n = 7)
GLPG2222
150 mg
q.d. (n = 16)
GLPG2222
300 mg
q.d. (n = 14)
Median age, years (range) 27.0 (21–58) 26.0 (20–37) 24.0 (18–35) 32.0 (19–47) 26.0 (19–59) 46.0
(19–53)
29.0 (19–42) 29.0 (18–35)
Median BMI, kg/m2 (range) 22.20
(16.3–25.7)
21.05 (18.7–25.1) 20.75 (14.1–23.3) 22.30 (18.5–26.8) 22.40
(18.3–23.7)
25.30
(21.2–33.6)
23.95
(19.9–31.5)
22.00
(18.4–34.3)
Male, n (%) 7 (63.6) 7 (70.0) 4 (40.0) 7 (50.0) 9 (64.3) 3 (42.9) 12 (75.0) 6 (42.9)
Median sweat chloride, mmol/L
(range)a
108.0
(91.5–114.5)
105.5
(86.0–114.5)
110.0
(96.0–113.0)
102.8
(82.0–119.5)
105.8
(100.0–123.0)
32.5
(25–90)
38.8 (16–99) 48.8 (14–88)
Median ppFEV1, % (range) 75.0 (43–92) 53.5 (35–80) 59.5 (39–113) 51.5 (40–88) 58.5 (38–92) 81.0
(37–97)
72.5
(41–113)
63.0 (37–99)
Mutation second allele, n (%) N/A
G178R 0 1 (6.3) 0
G551D 4 (57.1) 13 (81.3) 11 (78.6)
S1251 N 1 (14.3) 2 (12.5) 2 (14.3)
S1255P 1 (14.3) 0 1 (7.1)
S549R 1 (14.3) 0 0
Median duration of ivacaftor use,
weeks (range)
N/A 213.0
(17–233)
197.5
(74–337)
117.5
(41–216)
BMI, body mass index; ppFEV1, percent predicted forced expiratory volume in one second; N/A, not applicable; q.d., quaque die (once daily).
a Mean value from both arms.
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subjects in the ALBATROSS trial (Table 1).3.2. Safety and tolerability
In FLAMINGO, the most common TEAEs in subjects treated with
GLPG2222 were headache (n = 14), cough (n = 12), pulmonary exac-
erbation of CF (n = 8), and sputum increase (n = 8) (Table S3). In
ALBATROSS, headache (n = 10) and diarrhea (n = 8) were the most
common (Table S4). There were no deaths or TEAEs leading to treat-
ment discontinuation in either study. In GLPG2222-treated subjects,
treatment-related TEAEs were reported by 29.2% (14/48) of subjects
in FLAMINGO and 40.0% (12/30) in ALBATROSS. Most TEAEs were
mild or moderate (Table 2).
In the FLAMINGO study, serious TEAEswere reported in two subjects
in the placebo group and one in the GLPG2222 100 mg group, all of
whom experienced pulmonary exacerbation of CF. None were consid-
ered study drug-related. There were no serious TEAEs reported in the
ALBATROSS study (Table 2). In both studies, there were no clinicallyTable 2
Safety summary for the FLAMINGO and ALBATROSS studies (safety populations).
Parameter FLAMINGO (N = 59)
Pooled
placebo
(n = 11)
GLPG2222 50 mg
q.d. (n = 10)
GLPG2222 100 mg
q.d. (n = 10)
GLPG2222 20
q.d. (n = 14)
All TEAEs, n (%) 9 (81.8) 8 (80.0) 10 (100.0) 11 (78.6)
TEAEs n, (%)
Mild 6 (54.5) 4 (40.0) 7 (70.0) 8 (57.1)
Moderate 2 (18.2) 4 (40.0) 2 (20.0) 2 (14.3)
Severe 1 (9.1)a 0 1 (10.0)a 1 (7.1)b
Treatment-related
TEAEs, n (%)
2 (18.2) 2 (20.0) 6 (60.0) 5 (35.7)
Serious TEAEs,
n (%)
2 (18.2) 0 1 (10.0) 0
q.d., quaque die (once daily); TEAE, treatment-emergent adverse event.
a Pulmonary exacerbation of cystic fibrosis (not considered related to study drug).
b Bronchial secretion decrease, purulent discharge, and exercise tolerance increase.
c Headache.significant trends in mean and median laboratory parameters, ECG,
vital signs, or pulse oximetry values observed over time.
3.3. Efficacy
3.3.1. Sweat chloride concentrations
Inbothstudies,meanchanges frombaseline insweatchlorideconcen-
trationwere similar whether determined from themean of both arms or
the armwith the greatest volume. Results using the sweat chloride de-
rived fromthemeanof both armsarepresentedhere. In each study, base-
line concentrations were similar across groups. In subjects who received
placebo, sweat chloride levels increased over time in ALBATROSS but de-
creased in the FLAMINGO study, likely reflecting intra-subject variability
(Fig. 2A&B). Mean concentrations decreased in all GLPG2222 treatment
groups at days 15 and 29 compared with baseline (Fig. 2A&B). In the
FLAMINGO study, this decrease was dose-dependent up to 200 mg. On
days 15 and 29, least-squares (LS)-mean differences in the GLPG2222
200mg group versus placebo (95% confidence interval [CI]) were−11.2
(−19.1, −3.3; p = 0.0062) and −15.8 mmol/L (−23.2; −8.3; p b
0.0001), respectively. In the ALBATROSS study, the maximum decreaseALBATROSS (+ ivacaftor; N = 37)
0 mg GLPG2222 400 mg
q.d. (n = 14)
Placebo
(n = 7)
GLPG2222 150 mg
q.d. (n = 16)
GLPG2222 300 mg
q.d. (n = 14)
9 (64.3) 7 (100.0) 12 (75.0) 13 (92.9)
9 (64.3) 5 (71.4) 10 (62.5) 11 (78.6)
0 2 (28.6) 1 (6.3) 2 (14.3)
0 0 1 (6.3)c 0
1 (7.1) 5 (71.4) 4 (25.0) 8 (57.1)
0 0 0 0
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10
5
0
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GLPG2222 150 mg
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GLPG2222 200 mg
GLPG2222 400 mg
GLPG2222 50 mg
GLPG2222 100 mg
Fig. 2.Mean (±SE) change in sweat chloride concentration from baseline to days 15 and 29 using the mean value from both arms in (A) the FLAMINGO study (ITT, LOCF) and (B) the
ALBATROSS study (modified ITT, LOCF). *p b 0.05 (treatment group versus placebo). FLAMINGO: Pooled placebo, n = 11; GLPG2222 50 mg, n = 10; GLPG2222 100 mg, n = 10;
GLPG2222 200 mg, n = 14; GLPG2222 400 mg, n = 14. ALBATROSS: Placebo, n = 7; GLPG2222 150 mg, n = 15; GLPG2222 300 mg, n = 14. ITT, intent-to-treat; LOCF, last
observation carried over; SE, standard error.
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ference versus placebo was−11.7 mmol/L [95% CI−21.1,−2.2; p =
0.0170]). The results of the sensitivity analysis confirmed the primary
ANCOVA analysis (Table S5).Waterfall plots of the change from baseline
in sweat chloride concentration at day 29 are shown in Fig. S2A&B.
3.3.2. Pulmonary function
In the FLAMINGO study, there were no differences in the change in
ppFEV1 from baseline at days 15 and 29 between the pooled placebo
and GLPG2222 groups (Fig. 3A and Table S6). In the ALBATROSS study,
atday29, therewasatrendforhigherppFEV1withGLPG2222300mgver-
sus baseline, but improvements were not significant comparedwith pla-
cebo (LS-mean difference [95% CI] 3.0% [−1.5%, 7.5%], p = 0.1812)
(Fig. 3B and Table S6).Waterfall plots of change from baseline in ppFEV1
at day 29 are shown in Fig. S3A&B. The results of the sensitivity analysis
were similar to the results of the primary ANCOVA analysis (Table S6).
Trends in data for change in FEV1 from baseline were similar to those for
ppFEV1 in both studies (absolute FEV1 data are shown in Figs. S4 and S5).
3.3.3. Respiratory symptoms as measured by CFQ-R
CFQ-R respiratory symptom scale scores did not change significantly
in either study (Table S7).
3.4. Pharmacokinetics
Time to maximum observed plasma concentration (Tmax) of
GLPG2222 was independent of dose and occurred earlier with the oralsuspension (ALBATROSS study) compared with the tablet formulation
(FLAMINGO study), with a median Tmax of 1 h versus 2–3 h, respec-
tively. Overall, themean concentrations of GLPG2222 increased propor-
tional to dose in both studies.
Multiple oral doses of GLPG2222 had no effect on ivacaftor expo-
sures (ALBATROSS study); point estimates of the geometric mean ratios
for maximum observed plasma concentration of ivacaftor were close to
100%.4. Discussion
The objective of these studies was to expand upon prior preclinical
and phase 1 clinical studies of GLPG2222, providing further information
about safety, tolerability, and PK in CF subjects, as well as a preliminary
evaluation of efficacy. These datawill help to inform subsequent studies
with GLPG2222 in combination with other CFTR modulators, as part of
the compound's long-term clinical development.
GLPG2222 was well tolerated when administered alone in F508del
homozygous subjects (FLAMINGO) or in combination with ivacaftor in
subjects heterozygous for F508del and with a gating mutation (ALBA-
TROSS). Similar to earlier phase 1 data [19], the TEAEs reported in
both these phase 2 studies were mild to moderate in severity, and
typical for a CF study population (primarily respiratory, GI, and
infection-related).When comparing post-dose versus pre-dose spirom-
etry measurements in the current studies no significant differences
were observed, indicating a lack of bronchoconstriction. This is
reassuring as such effects (chest tightness, dyspnea) have been reported
AB
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placebo, n = 11; GLPG2222 50 mg, n = 10; GLPG2222 100 mg, n = 10; GLPG2222 200 mg, n = 14; GLPG2222 400 mg, n = 14. ALBATROSS: Placebo, n = 7; GLPG2222 150 mg, n =
15; GLPG2222 300 mg, n = 14. ITT, intent-to-treat; LOCF, last observation carried over; ppFEV1, percent predicted forced expiratory volume in one second; SE, standard error.
705S.C. Bell et al. / Journal of Cystic Fibrosis 18 (2019) 700–707in some subjects and healthy volunteers receiving their first administra-
tion of lumacaftor/ivacaftor [7,8,21,22]. There were no permanent dis-
continuations of GLPG2222due to TEAEs in either of the present studies.
The PK of GLPG2222 was consistent with previous studies.
GLPG2222 did not impact the PK of ivacaftor. In both studies, there
was a decrease in sweat chloride concentration, confirming on-target
activity of GLPG2222 [23]. The 400 mg dose of GLPG2222 provided the
highest exposure, but this did not translate to the greatest decrease in
sweat chloride, which was observed at the 200mg dose. The difference
between these doses was less pronounced at day 15 comparedwith day
29. This leads us to postulate that a plateau may be reached at 200 mg
and numerically different results between doses at or above 200 mg
may be related to variability and/or limited subject numbers. Sweat
chloride concentrations increased over time in the placebo group of
the ALBATROSS study. The reasons for this are unclear, however base-
line sweat chloride levels (i.e. on ivacaftor treatment) were low in
these subjects, and when baseline sweat chloride concentrations ap-
proach normal levels it becomes more difficult to determine an effect.
In all treatment arms, ivacaftor exposure levels remained stable
throughout the study (data not shown), suggesting adherence to
ivacaftor was also stable. A substantial effect of GLPG2222 on lung func-
tion was not expected, as only modest effects have generally been re-
ported in studies of other drugs with a similar mechanism of action
and activity on CFTR in F508del homozygous subjects [6–9,12]. Our
findings are therefore consistent with data reported by others showing
that Type I CFTR correctors partially restore F508del CFTR to the plasmamembranewhere it can reside as a low activity CFTR channel. For exam-
ple, in a phase 2 study, lumacaftor did not affect lung function in doses
up to 200 mg q.d. but did exhibit a dose–response effect on sweat chlo-
ride levels [6], while at higher doses there was a dose-related decline in
FEV1 [7]. When lumacaftor was combined with ivacaftor in a phase 3
trial, a mean 2.6–4 percentage point increase in FEV1 was reported for
those receiving the combination compared with placebo (p b 0.001)
[8]. In a phase 2 trial of tezacaftor plus ivacaftor, a small but significant
improvement in ppFEV1 was reported (3.75 percentage points) in
F508del homozygous subjects [14]; an observation confirmed at phase
3 [12]. In subjects whowere heterozygous for F508del and a CFTR resid-
ual function mutation, tezacaftor plus ivacaftor significantly increased
ppFEV1 by 2.1 percentage points compared with ivacaftor alone [24].
By comparison, the greatest increase in ppFEV1 in the present studies
was an increase of 2.6 percentage points versus placebo in F508del het-
erozygous subjects in theALBATROSS study, however this improvement
was not significant.
Limitations of the current studies include the low subject numbers in
each group for the efficacy outcomes. As safety was the primary end-
point and in vitro data and literature on mechanistically similar CFTR
modulators indicated only small changes in ppFEV1 were expected,
the studieswere not powered to detect differences in efficacy outcomes,
including FEV1. Also spirometry data may have been confounded by the
higher baseline FEV1 values in the placebo versus the test groups, mak-
ing interpretation difficult (as subjects with lower lung function may
not have responded as well to active treatment as those with higher
706 S.C. Bell et al. / Journal of Cystic Fibrosis 18 (2019) 700–707function at baseline). However, FEV1 is inherently variable and this dif-
ference between groups may have occurred by chance due to random-
ization of small subject numbers. It is expected that, in combination
with a potentiator, GLPG2222 will demonstrate clinical efficacy on
FEV1 in F508del homozygous subjects based on in vitro data and com-
parisons with known dual combinations.
Development of combination therapies is challenging and eval-
uation of single agents, as undertaken in the FLAMINGO study, mit-
igates potential safety risks when combining two or more drugs. It
also provides a step-wise approach to understanding safety and ef-
ficacy of compounds and allows fine-tuning of dose selection in
subsequent combination therapies. Other CFTR correctors are in
development for use in combination therapy for CF. For example,
the next-generation correctors VX-659 (NCT03224351 and
NCT03029455), VX-445 (NCT03227471), VX-440 (NCT02951182),
and VX-152 (NCT02951195) have demonstrated improvements in
CF outcomes when given with tezacaftor and ivacaftor in phase 1
or 2 studies in subjects homozygous for F508del or heterozygous
for F508del and a minimal function CFTR mutation [25–28]. These
and other investigational combinations, such as the triple combina-
tion PTI-428/PTI-801/PTI-808 (NCT03500263), may expand the
treatment armamentarium available to CF patients in the future.
5. Conclusions
A range of new CFTR modulators are currently under evaluation
through phase I to III clinical trials and the therapeutic landscape is
changing rapidly, resulting in fewer modulator-naïve subjects available
for clinical studies. This has important implications for the design and
conduct of future trials, such as the evaluation of treatment combina-
tions. Findings from FLAMINGO and ALBATROSS demonstrated that
GLPG2222 is well tolerated both alone and in combination with
ivacaftor, with preliminary data suggesting partial correction of CFTR
function and on-target activity. These outcomes will inform the future
clinical evaluation of GLPG2222 within this dynamic environment, in
particular with regards to its use in combinations with additional CFTR
modulators.
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